Entyvio is a brand-name drug prescribed for ulcerative colitis and Crohn’s disease. The medication is available as an IV infusion and subcutaneous injection. Entyvio is a biologic drug that’s ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Ulcerative colitis and Crohn’s disease are types of inflammatory bowel disease (IBD) that cause irritation and inflammation in the gastrointestinal tract (GI tract). The immune system attacks the GI ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio pre-filled pen for subcutaneous injection contains the active ...